This protocol addresses patients with Fanconi anemia and severe bone marrow failure for whom hematopoietic cell transplantation (HCT) is not possible, not preferred, or carries an exceptional risk. Exceptional-risk patients include those aged 35 or older, those with severe organ dysfunction, a pre-existing malignancy, or a life-threatening systemic infection.
Androgen therapy was the prior treatment step in this setting. The expected response — stabilization of falling blood counts or an increase in hemoglobin or platelet counts within three to four months — was not achieved.
This protocol defines the next step after that failure.
Granulocyte colony-stimulating factor (G-CSF) is considered in this setting to address neutropenia associated with recurrent or serious infections.
Treatment goal: Improvement in the neutrophil count.
If blood counts decline to severe levels and cure by HCT is not possible or preferred, alternative therapies may maintain blood counts and quality of life in patients with FA.
Patients with an exceptional risk of HCT-related mortality (e.g., patients with severe organ dysfunction, those who are 35 years or older, and those with pre-existing malignancies or life-threatening systemic infections) may consider alternative treatment options first, such as the use of androgens.
The cytokines granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can improve the neutrophil count in patients with FA; however, GM-CSF is no longer available for clinical use.
Treatment with G-CSF may be considered if the neutropenia is associated with recurrent or serious infections, particularly if the neutrophil count is persistently below 500/mm3 or as a short-term bridge to transplant.
Treatment should generally be discontinued if the neutrophil count fails to improve after eight weeks of G-CSF therapy.
View source ↗